• Aucun résultat trouvé

Appendix 4.1.1 - Medical Directive for the Provision of Immunization Services

N/A
N/A
Protected

Academic year: 2022

Partager "Appendix 4.1.1 - Medical Directive for the Provision of Immunization Services"

Copied!
5
0
0

Texte intégral

(1)

Appendix 4.1.1 - Medical Directive for the Provision of Immunization Services

Public health nurses and community health nurses employed in First Nations communities may provide immunization services to those eligible for publicly funded vaccine subject to the policies, standards and guidelines of the New Brunswick Immunization Program. Information on these policies and guidelines can be found in the latest edition of the New Brunswick Immunization Program Guide (NBIPG):

http://www2.gnb.ca/content/gnb/en/departments/ocmoh/for_healthprofessionals/cdc/

NBImmunizationGuide.html

Under this Directive (Policy 2.5 - Medical Directive Required for the Provision of Immunization Services), the nurse must be competent in all essential immunization practices as detailed in the Public Health Agency document: Immunization Competencies for Health Professionals http://www.phac-aspc.gc.ca/im/

ic-ci/index-eng.php.

Nurses should refer to the following documents for the required information for each practice:

Essential Immunization

Practices Reference

Competencies for

Immunization Providers • NBIPG- Policy 2.4

https://www2.gnb.ca/content/dam/gnb/Departments/h-s/

pdf/en/CDC/HealthProfessionals/NBIPG-policy2-4-e.pdf Communication • NBIPG -Standard 3.2 - Communicating Effectively About

Immunization: A Guideline for Immunization Providers in New Brunswick

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-standard3-2-e.pdf

• NBIPG- Policy 2.6 - Consent for Immunization

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-policy-2-6-e.pdf

• Canadian Immunization Guide (CIG)- Part 1 - Key

Immunization information- Communicating Effectively about Immunization

https://www.canada.ca/en/public-health/services/

publications/healthy-living/canadian-immunization- guide-part-1-key-immunization-information/page-5- communicating-effectively-immunization.html Vaccine Storage and Handling • NBIPG -Standard 3.4 - Vaccine Storage and Handling

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-standard3-4-e.pdf

• CIG- Part 1 - Key Immunization information- Storage and Handling of Immunizing Agents

https://www.canada.ca/en/public-health/services/

publications/healthy-living/canadian-immunization-guide- part-1-key-immunization-information/page-9-storage- handling-immunizing-agents.html

Administration of immunizing agents including pre-

vaccination assessment

• CIG- Part 1 - Key Immunization information- Vaccine Administration Practices

https://www.canada.ca/en/public-health/services/

publications/healthy-living/canadian-immunization-guide- part-1-key-immunization-information/page-8-vaccine- administration-practices.html

(2)

Essential Immunization

Practices Reference

Adverse events following

immunization • NBIPG- Policy 2.7 - Adverse Events Following Immunization (AEFIs)

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-policy2-7-e.pdf

• NBIPG-Standard 3.8 - Reporting of Adverse Events Following Immunization in New Brunswick

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-standard3-8-e.pdf

• NBIPG- Appendix 5.1- Protocol for the management of immunization-related anaphylaxis in non-hospital settings http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/ANAPHYLAXIS-management_

EN.pdf

• CIG -Part 2 – Vaccine Safety

https://www.canada.ca/en/public-health/services/

publications/healthy-living/canadian-immunization-guide- part-2-vaccine-safety.html

Documentation • NBIPG- Standard 3.5 - Recording, Reporting and Releasing Immunization Information

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-standard3-5-e.pdf Populations requiring special

consideration • NBIPG-Policy 2.11 - Populations Requiring Special Consideration

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-policy2-11-e.pdf

• CIG- Part 3 - Vaccination of Specific Populations https://www.canada.ca/en/public-health/services/

publications/healthy-living/canadian-immunization-guide- part-3-vaccination-specific-populations.html

(3)

Nurses must administer vaccines against these diseases in accordance with:

Reference Eligible Individual or

Population • NBIPG standard/guideline 3.3- Eligibility Criteria for Publicly Funded Vaccines/Biologics

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/HealthProfessionals/NBIPG-standard3-3-e.pdf Schedule • NBIPG standard/guideline 3.1 - Routine Immunization

Schedule

http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/

en/CDC/Immunization/RoutineImmunizationSchedule.pdf

• NBIPG Appendix 4.4- An Assessment Tool to Determine the Validity of Vaccine Doses

https://www2.gnb.ca/content/dam/gnb/Departments/h-s/

pdf/en/CDC/HealthProfessionals/NBIPG-appendice4-4.pdf

(4)

Product PRODUCT ANTIGENS

Diphtheria, Tetanus , Acellular Pertussis, Inactivated Polio &

Haemophilus Influenza Type b (DTaP-IPV-Hib) Haemophilus Influenzae Type b (Hib)

Hepatitis A - pediatric (HA) Hepatitis A - adult (HA) Hepatitis B - pediatric (HB) Hepatitis B - adult (HB) Hepatitis B- dialysis (HB) Hepatitis A and B adult (HAHB) Hepatitis A & B junior (HAHB) Human Papillomavirus (HPV) Inactivated polio (IPV) Influenza (Inf)

Measles, Mumps, Rubella (MMR)

Measles, Mumps, Rubella, Varicella (MMRV) Meningococcal conjugate (Men-C-C)

Meningococcal conjugate A,C,Y & W-135 (Men-C-ACWY) Meningococcal-B (Men-B)

Pneumococcal conjugate 13-valent (Pneu-C-13) Pneumococcal polysaccharide 23 -valent Rabies (Rab)

Rotavirus (RV)

Tetanus Toxoid, Diphtheria (Td)

Tetanus, Diphtheria, Acellular Pertussis (Tdap)

Tetanus, Diphtheria, Acellular Pertussis, Inactivated Polio (Tdap-IPV) Varicella (Var)

ANAPHYLAXIS

Diphenhydramine Hydrochloride (Benadryl) Epinephrine

Dosage, Route and

administration instructions • Product Monograph for each vaccine CIG-

https://www.canada.ca/en/public-health/services/canadian- immunization-guide.html

Contraindications • Product Monograph for each vaccine CIG-

(5)

Medical Directive for the Provision of Immunization Services

The Regional Health Authority or the First Nations Community Health responsible for the provision of immunization services must have in place ongoing quality control processes to ensure adherence to the conditions of this Medical Directive and to the policies, standards and guidelines of the New Brunswick Immunization Program.

Regional Medical Officer of Health:

(Name) (Signature) (Date)

The Regional Health Authority or the First Nations Community Health

Acknowledgement of the Medical Directive for the Provision of Immunization Services

I have met the conditions outlined in this Medical Directive:

(Nurse’s Name)

(Signature) (Date)

Program Director:

(Name) (Signature) (Date)

Name of organization:

Références

Documents relatifs

As demonstrated in a number of controlled studies conducted among 12–15 month old infants, in children <18 years and in adults, inactivated HAV vaccines can be administered

re-examined. Serologic diagnosis of acute and chronic viral 29) hepatitis.. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface 30) antigen-positive

In situations where there is a particularly high risk of mortality among children under age 9 months, such as refugee camps, hospitalized infants, and HIV-infected infants, two doses

Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary

The proportion of children who develop protective antibody levels following measles vaccination depends on the presence of inhibitory maternal antibodies and the immunologic

One dose of quadrivalent meningococcal conjugate in children aged 2–10 years was observed to induce greater rSBA titres for all four capsular groups compared to those

The laboratory correlate for the induction of immunological memory following meningococcal serogroup C conjugate (MCC) vaccination used to be an SBA titre greater than or equal

The rates of reported aseptic meningitis following mumps vaccination range from lowest with the Jeryl Lynn strain (<1 per 100 000 doses) to rates over 25 per 100 000 doses